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Many immunostimulatory drugs, such as agonistic anti-
bodies to CD137 and interleukin (IL)-2, generate effec-
tive antitumor immune responses in preclinical studies,
but demonstrate serious toxicity profiles after systemic
administration, which hampers their clinical application.
We recently discovered that a combination of anti-
CD137 with an extended half-life IL-2-Fc fusion protein
(lacking Fc receptor binding) had pronounced anti-
tumor activity, but also induced toxic levels of systemic
inflammatory cytokines. In order to reduce their in vivo
toxicity and enhance the therapeutic window, anti-
CD137 and IL2-Fc were anchored to the surface of
PEGylated liposomes (Lipo-aCD137/IL2-Fc), which
served as a scaffold to deliver sufficient quantities of
immunostimulatory cytokines to primary and metastatic
tumors following systemic administration, while mini-
mizing systemic toxicity. In the aggressive, poorly
immunogenic B16F10 melanoma model, soluble mix-
tures of anti-CD137 and IL2-Fc (aCD137/IL2-Fc) dra-
matically retarded tumor growth, but also elicited lethal
toxicity in 100% of animals following 2 injections;
reduced doses of this combination therapy exhibited less
toxicity but also lost therapeutic efficacy. In striking
contrast, mice treated with Lipo-aCD137/IL2-Fc showed
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significant tumor growth inhibition comparable to the
soluble drug treatment, but with negligible in vivo toxi-
city. High levels of systemic inflammatory cytokines
were triggered after intravenous administration of
aCD137/IL2-Fc while minimum levels of cytokines were
detected in Lipo-aCD137/IL-2-treated animals. Both
aCD137/IL2-Fc and Lipo-aCD137/IL2-Fc enhanced the
infiltration of cytotoxic T lymphocytes (CTL) and NK
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cells as well as the IFN-g secretion in tumors. However,
Lipo-CD137/IL-2 quickly cleared from the circulation
after bolus IV administration and accumulated in tumor
via the enhanced permeation and retention effect; while
soluble aCD137 and IL2-Fc showed prolonged blood
circulation profiles, which persistently activated circulat-
ing T lymphocytes, leading to toxicity and decreased
survival. These results demonstrate that potent immu-
nomodulators anchored to liposomes exhibit signifi-
cantly reduced in vivo toxicity while retaining anti-
tumor efficacy compared to their soluble forms at
equivalent cytokine doses after systemic administration.
Reduced in vivo toxicity was due to the biodistribution
and pharmacokinetic profiles offered by the liposome
scaffold.
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